Cybin Inc. (NEO: CYBN) (OTCQB: CLXPF) Files Patent, Adds New Dimension to Development Strategy
Digital therapeutics platform is proprietary to Cybin and the subject of the company’s 13th patent application Company focused on utilizing, leveraging cutting-edge technologies to support drug-development candidates Cybin is confident this added focus will better enable the evaluation of patient outcomes Cybin (NEO: CYBN) (OTCQB: CLXPF), a biotechnology company, has taken another step forward in its strategic focus on progressing psychedelic therapeutics, with the filing of its 13th provisional patent application (https://ibn.fm/xTawm). In addition to the patent filing, the company has also advanced the build-out of its digital therapeutics strategy. “The digital therapeutics platform, which is proprietary to Cybin and the…